- “PresbyCustom”: New customizable contact lenses to correct presbyopia
Presbyopia is a widespread problem in the population over 45 years, so it is especially relevant to develop a new multifocal contact lenses based on the optimization of depth of focus through combining different types of optical aberrations, with an easy fitting, with significant positional stability, and customizable according to the specific needs of each ...
- Body Vision Medical Receives FDA Clearance for LungVision 2.0 System, a Part of LungVision Platform, Demonstrated at ATS 2019
Physicians explore how the cutting-edge technology helps them visualize, access and biopsy small lung lesions in real time with high accuracy, while in the standard bronchoscopy suite.
Body Vision Medical, a medical device company specializing in augmented real-time imaging, artificial intelligence and intra-body navigation, announced today that it has received clearance from the U.S. Food and ...
- Vascular Flow Technologies Forges Strategic Partnership with Biovic to Develop the new Avatar SLF™ Vascular Graft
Vascular Flow Technologies, the medical device company who developed the proprietary Spiral Laminar Flow (SLF™) technology to re-establish natural blood flow for enhanced patient outcomes, today announces the successful conclusion of a strategic intellectual property out-licencing agreement with Biovic Sdn bhd.
Biovic are a Malaysian based high tech biomedical company focussed on meeting the needs of ...
- Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompé Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy
Behind the development of cenegermin are decades of Italian research, stemming from the studies of Rita Levi Montalcini, winner of the Nobel Prize in Medicine for the discovery of the nerve growth factor (NGF).
In 2015, the product was designated as an orphan drug in Europe for the treatment of neurotrophic keratitis, a rare eye disease ...
- Mel-Mont Medical, LLC announces the development of Mía by XytoTest®, a self-collected cervical sample that seeks to eradicate cervical cancer
Mía by XytoTest® is a preventive comprehensive diagnostic system developed and patented by the American company, Mel-Mont Medical, LLC founded in 2014 by Frank Meléndez, MSc. and Liliana Montes, MSc. both medical device developers. This innovative system includes a medical device that allows women to self-collect cervical cells in any environment without assistance, to later ...
- New NK1 receptor antagonists for the treatment of cancer and other illnesses related to Substance P (SP)
Researchers from the Faculty of Pharmacy at the University of Seville and the Institute of Chemical Research of the CSIC have developed a series of new compounds with high activity and selectivity for the treatment of distinct types of can-cer. The invention is directed towards the prevention and/or treatment not only of cancer but of ...